At present there is no commercially available product for humans that can be sprayed onto wounds in emergency situations to promptly alleviate pain, minimise bleeding, provide antisepsis and create a protective barrier.
We have demonstrated the commercial success of our lead product, Tri-Solfen®, for animals. Data from these animal studies suggests that a similar formulation may be equally safe and effective for use on humans. A multi-function topical formulation, such as Tri-Solfen®, has the potential to revolutionise the acute management of open wounds in humans, to alleviate suffering, to reduce the risk of blood loss and infection and improve recovery, in the same manner that it has done in animals.
We are therefore undertaking research and development to optimise the formulation and packaging of Tri-Solfen® for human use, and to investigate regulatory options for bringing the product to market.
Chronic wounds affect millions of people globally, which is expected to rise significantly due to the increasing proportion of elderly patients living longer. There are three main types of chronic wounds; venous leg ulcers, diabetic foot ulcers and pressure ulcers. We are initially focused on the development of our technology for the treatment of venous leg ulcers, which represent 80% of all chronic ulcers.
Cleansing chronic wounds of local barriers, such as dead tissue, is known as debridement and is an essential process to facilitate efficient healing. It has been shown that faster and more complete healing is achieved with more frequent debridement.
However, debridement of chronic wounds is not well tolerated and patients will often ask clinicians to stop before the procedure is completed, or avoid the procedure, because of the pain and discomfort. This pain also extends beyond completion of the procedure.
Patients with venous leg ulcers report pain to be the worst aspect of having an ulcer. Chronic pain is highly complex, may extend over months or years, and has enormous implications for a patient’s quality of life, causing decreased activities of daily living, sleep disturbance, reduced mobility and social withdrawal.
It has been shown that when patients with venous leg ulcers feel an ease or absence of pain they interpret it as a positive sign of wound healing, which can make them feel hopeful and optimistic.
Supported by our trial data from our approved animal product (Tri-Solfen®), we have agreed a clinical development protocol for human use of our technology in venous leg ulcers.
Future near-term opportunities we have identified for our technology include the treatment of traumatic wounds caused by surgical procedures and mass trauma situations such as accidents, military conflict and natural disasters.